Compare Expedia Group Inc (EXPE) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Expedia Group Inc vs TransMedics Group Inc — how do they compare? Expedia Group Inc trades at $272.26 (market cap $32.42B), while TransMedics Group Inc trades at $77.75 (market cap $2.74B). The key difference: Expedia Group Inc is far larger — about 11.8× TransMedics Group Inc's market cap, and Expedia Group Inc pays a 0.71% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Expedia Group Inc for 47 Days and TransMedics Group Inc for 24 Days on average.
| EXPE | TMDX | |
|---|---|---|
Market Cap | $32.42B | $2.74B |
Volume | 1,940,671 | 949,331 |
Sector | Consumer Cyclical | Health |
52-Week High | $339.13 | $150.42 |
52-Week Low | $188.51 | $61.99 |
Typical Hold Time | 47 Days | 24 Days |
Enterprise Value | $30.98B | $3.13B |
Dividend Yield | 0.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Expedia Group (EXPE) trades at $271.44, up 4.86% today, showing strong momentum after recent earnings beats. The stock exhibits a bullish technical signal, trading near resistance at $275, with solid fundamentals including a P/E of 16.99 and robust revenue growth to $14.73B in 2025. Recent news highlights competitive threats from AI agents but also underscores Expedia's strategic partnerships and B2B booking strength.
The outlook remains positive with a consensus price target of $335.06, implying 23% upside, supported by earnings momentum and market share gains. Key risks include AI disruption in travel booking and competitive pressures. Institutional sentiment is mixed but leans bullish, with growth in operating cash flow to $3.9B in 2025 providing a solid foundation.
TransMedics Group (TMDX) trades at $80.69, down 0.47% on the day, amid a bearish technical signal and mixed earnings performance. The company reported strong revenue growth to $605.49M in 2025 with a net income margin of 22.69%, but recent quarters have seen earnings misses. Analyst sentiment remains positive with a consensus price target of $99.75 and a 69% buy rating, though news flow includes investigations into fiduciary duties.
The outlook balances robust fundamentals against near-term headwinds. Upside potential exists from the high analyst target and strong profitability metrics like a 36.28% ROE, but risks include earnings volatility, margin pressure, and ongoing legal scrutiny. The stock's current valuation at a P/E of 20.47 offers a reasonable entry if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Expedia Group Inc
Expedia is the world's largest online travel agency by bookings, offering services for lodging (75% of total 2021 sales), air tickets (3%), rental cars, cruises, in-destination, and other (15%), and advertising revenue (7%). Expedia operates a number of branded travel booking sites, including Expedia.com, Hotels.com, Travelocity, Orbitz, Wotif, AirAsia, and Vrbo. It has also expanded into travel media with the acquisition of Trivago. Transaction fees for online bookings account for the bulk of sales and profits.
Read more on EXPE →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
